



## **Kane Biotech Inc.**

**Symbol:** TSXV: KNE | OTCQB: KNBIF

**Sector:** Biotech

**Purpose:** Raise Awareness / Open Market Buying

Kane Biotech Inc. is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. When protected by a biofilm, bacteria become highly resistant to antibiotics, antimicrobials, biocides and host immune responses. This resiliency contributes to numerous human health related problems. Kane Biotech's mission is to capitalize on this large, addressable market by licensing its proprietary anti-biofilm technologies to global industry players. Kane Biotech's lead product is revyve™ Antimicrobial Wound Gel which has been approved by both Health Canada and the US FDA. The Company has 20 employees and is headquartered in Winnipeg, Manitoba, Canada.

### **Investor Bullet Points:**

- US Launch of FDA approved revyve wound gel in 2024
- Increasing ROW distribution network
- Anticipated EBITDA positive at end of 2025

### **Robert Huizinga – Executive Chairman**

Dr. Robert Huizinga co-founded Aurinia Pharmaceuticals Inc. in Victoria Canada (\$AUPH) which went from \$10 million to a peak valuation of >\$4 billion USD. He led the Phase I-III development of voclosporin for lupus nephritis. During his time at pharma, Dr. Huizinga has raised over \$500 million USD on the public stock markets, has presented and defended data to the FDA, EMA, Health Canada, PMDA, BfArM, and the Japanese regulator (PMDA). He saw voclosporin through the first-year commercialization with sales >\$100 million USD, and now is a consultant to various companies as well as the Executive Chair of Kane Biotech Inc. in Canada.